Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

October 12, 2017: By Jon Swedien

AlconAlcon announced Sept. 29 that its AcrySof intraocular lenses (IOLs) have been implanted more than 100 million times.

In celebration, Alcon launched its “100 Million Moments Made” campaign, which includes resources designed to showcase the accomplishment in markets around the globe, the Fort Worth, Texas, company said.

The first recorded implantation of an AcrySof IOL was in the UK in 1990. Since then, the platform has grown to include solutions for correcting astigmatism (AcrySof IQ Toric) and presbyopia (AcrySof IQ ReSTOR and PanOptix), Alcon said.

The AcrySof family of IOLs includes brands available in approximately 120 markets: AcrySof IQ, AcrySof IQ Toric, AcrySof IQ ReSTOR, AcrySof IQ ReSTOR Toric, AcrySof IQ PanOptix, and AcrySof IQ PanOptix Toric.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility